Gilead Sciences has been exclusively granted licensed use of Genmab’s DuoBody technology, in an aim to create a platform for the development of antibodies targeting HIV.
Gilead will pay Denmark-based Genmab $5 million upfront, followed by regulatory and sales milestone up to $277 million for the first product.
The bispecific antibody technology from Genmab uses antibodies to efficiently target disease and cease the bacterial activity. The platform will strengthen Gilead's presence in a growing field of HIV research.
Read the Country Caller Coverage